Vitamine K Antagonist (VKA) Treatment

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

L
LabcorpNC - Burlington
1 program
LabPad® point-of-careN/A1 trial
Active Trials
NCT04117048Completed128Est. Apr 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
LabcorpLabPad® point-of-care

Clinical Trials (1)

Total enrollment: 128 patients across 1 trials

NCT04117048LabcorpLabPad® point-of-care

INR at Home Measurement by the LabPad® Point-of-care in Patients on Vitamin K Antagonist Drugs (VKA)

Start: Oct 2019Est. completion: Apr 2020128 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space